真实世界中骨转换标志物的使用:对治疗决策和骨折的影响
该回顾性美国真实世界数据研究纳入2008年1月至2018年6月新诊断骨质疏松的≥50岁患者,发现骨转换标志物检测与治疗决策相关(OR 1.14,95%CI 1.13-1.15),并与较低骨折风险相关(OR 0.87,95%CI 0.85-0.88),支持其在临床实践中的应用。
要点
- 骨转换标志物检测率逐年显著增加,平均年变化+8.1%(95%CI 5.6-9.0,p=0.01)。
- 检测组患者做出治疗决策的可能性显著更高(OR 1.14,95%CI 1.13-1.15)。
- 检测与较低骨折风险相关(OR 0.87,95%CI 0.85-0.88)。
核心结论
- 在大量异质性 presumed osteoporosis 患者中,骨转换标志物检测与治疗决策相关,可能促成使用后脆性骨折减少。
研究设计与样本
- 回顾性美国真实世界数据研究,使用Truven MarketScan® Commercial Claims and Encounters和Medicare Supplemental and Co-ordination of Benefits数据库,纳入2008年1月至2018年6月新诊断骨质疏松的≥50岁患者。
- 骨质疏松通过明确索赔、与骨质疏松相关的脆性骨折事件或处方抗骨吸收或合成代谢治疗确定。
- 检测患者与未检测患者按1:1倾向评分匹配,使用广义估计方程模型估计比值比(OR)和95%置信区间(CI)。
主要发现
- 457,829例骨质疏松患者中,6,075例在诊断后至少接受1次骨转换标志物检测;其中1,345例在检测后≤30天内做出独特治疗决策。
- 接受骨转换标志物检测的患者百分比每年显著增加(平均年变化+8.1%;95%CI 5.6-9.0;p=0.01)。
- 检测组患者做出治疗决策的可能性显著更高(OR 1.14;95%CI 1.13-1.15)。
- 检测与未检测相比,骨折风险比值更低(OR 0.87;95%CI 0.85-0.88)。
临床怎么用
- 原文结论指出骨转换标志物检测与治疗决策相关,可能促成脆性骨折减少,支持其在临床实践中的应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The use of bone turnover marker (BTM) testing for patients with osteoporosis in the USA has not been well characterized. This retrospective US-based real-world data study found BTM testing has some association with treatment decision-making and lower fracture risk in patients with presumed osteoporosis, supporting its use in clinical practice. INTRODUCTION: The purpose of this study was to characterize bone turnover marker (BTM) testing patterns and estimate their clinical utility in treatment decision-making and fragility fracture risk in patients with osteoporosis using a retrospective claims database. METHODS: Data from patients aged ≥ 50 years with newly diagnosed osteoporosis enrolled in the Truven MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Co-ordination of Benefits databases from January 2008 to June 2018 were included. Osteoporosis was ascertained by explicit claims, fragility fracture events associated with osteoporosis, or prescribed anti-resorptive or anabolic therapy. BTM-tested patients were 1:1 propensity score matched to those untested following diagnosis. Generalized estimating equation models were performed to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for testing versus no testing on both treatment decision-making and fragility fracture. RESULTS: Of the 457,829 patients with osteoporosis, 6075 were identified with ≥ 1 BTM test following diagnosis; of these patients, 1345 had a unique treatment decision made ≤ 30 days from BTM testing. The percentage of patients receiving BTM tests increased significantly each year (average annual % change: + 8.1%; 95% CI: 5.6-9.0; p = 0.01). Patients tested were significantly more likely to have a treatment decision (OR: 1.14; 95% CI: 1.13-1.15), and testing was associated with lower odds of fracture versus those untested (OR: 0.87; 95% CI: 0.85-0.88). CONCLUSION: In this large, heterogeneous population of patients with presumed osteoporosis, BTM testing was associated with treatment decision-making, likely leading to fragility fracture reduction following use.
引用
- Lane NE, Saag K, O'Neill TJ, et al. Real-world bone turnover marker use: impact on treatment decisions and fracture. Osteoporos Int. 2020. PMID: 33236195. doi:10.1007/s00198-020-05734-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。